Back in September of 2010 he was also names to the Board of another technology company that deals with urology and cancer therapies. Since his tenure at the FDA it sounds like von Eschenbach is returning to his roots with using his expertise in the clinical area of healthcare. BD
Viamet Pharmaceuticals has landed a healthcare heavyweight in naming prostate cancer expert and former U.S. Food and Drug Administration commissioner Dr. Andrew von Eschenbach to the company’s board of directors.
Durham, North Carolina-based Viamet has a proprietary technology that identifies and blocks certain enzyme targets. The technology can be used to develop new drugs and Viamet last year signed a licensing agreement with Novartis (NYSE:NVS) that could be worth more than $200 million if Viamet is able to develop certain enzyme inhibitors for the Swiss drug company.